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10 mg/kg.9 Further studies on the pharmacokinetics 
of oxantel pamoate are needed to conﬁ rm its safety 
proﬁ le when given at higher doses and when co-
administered with diﬀ erent drugs.
The use of oxantel pamoate combination chemo-
therapy in deworming programmes also faces a 
number of hurdles. First, oxantel pamoate has yet 
to be included on the WHO Essential Medicines List. 
Second, oxantel pamoate combinations are not readily 
available. Third, the large-scale donation programmes 
of albendazole and mebendazole mean that there 
are fewer ﬁ nancial incentives for the private sector 
to manufacture and distribute new anthelmintics.10 
Strategic partnerships will need to be established to 
address these issues if oxantel pamoate combination 
therapies are to be brought to international markets. 
At a time when some of the public health eﬀ ects 
of current deworming programmes are being 
questioned,11 the discovery of potent compounds 
to eﬀ ectively decrease soil-transmitted helminth 
morbidity in vulnerable groups remains a priority. 
Oxantel pamoate is certainly not a panacea, with 
imperfect cure rates for whipworm infection and 
little eﬀ ect on roundworm and hookworm infections, 
but few other alternatives are available (albendazole–
ivermectin dual therapy7,12 being one such alternative 
that has its own limitations). Concomitantly, 
deworming is an interim solution to reducing 
morbidity attributed to soil-transmitted helminths. 
Improvements in sanitation are a pre requisite to 
sustainably improve the health of at-risk populations.
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Artefenomel: a promising new antimalarial drug
New drugs are needed to treat malaria. Artefenomel 
(OZ439), a trioxolane that shares the peroxide 
pharma cophore of highly eﬀ ective artemisinins,1 
has been pro gressing through development, and 
results reported by Aung Pyae Phyo and colleagues2 
in The Lancet Infectious Diseases add to its promise. 
As with every new potential antimalarial drug, 
artefenomel has advantages and disadvantages. 
Before considering these issues, it is appropriate to ask 
fundamental questions, such as why do we need new 
drugs for malaria and what drug characteristics are 
most needed?
First, available drugs are limited by drug resistance. 
Artemisinin-based combination therapy is recom-
mended for the treatment of falciparum malaria and is 
eﬀ ective against other plasmodial species. Artemisinin 
resistance, manifested as delayed parasite clearance 
after therapy, is established in southeast Asia.3 Less 
publicised is decreased activity of partner drugs, with 
decreased parasite sensitivity and changing sensitivity 
patterns over time documented for several drugs in 
diﬀ erent regions.4 Recently in Cambodia, delayed 
parasite clearance as well as actual high failure rates 
have been seen after treatment of uncomplicated 
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malaria with dihydroartemisinin plus piperaquine, 
presumably because of decreased responsiveness to 
both drugs.5,6 New antimalarial drugs that are not 
aﬀ ected by current resistance mechanisms are needed.
Second, available drugs require multiple doses. 
Artemisinin-based combination therapies are given 
once or twice daily for 3 days. An eﬀ ective single-dose 
regimen, oﬀ ering improved compliance and cost, 
would be a huge advance. The identiﬁ cation of new 
agents eﬀ ective after a single dose is a high priority.
Third, most available drugs are not highly active 
against non-erythrocytic and sexual stages. 
Treatment of malaria requires action against asexual 
erythrocytic parasites, which are responsible for 
all disease manifestations. Added beneﬁ t would 
come from action against other stages to facilitate 
chemoprevention (by killing liver stages before they 
elicit clinical illness) and transmission blocking (by 
killing sexual stages before they infect mosquitoes).
Fourth, artemisinins are natural products, com-
plicating maintenance of stable drug supplies and 
pricing. This challenge has been partly overcome with 
the development of bioengineered artemisinic acid 
in yeast.7 Bioengineered artemisinin has contributed 
to the worldwide supply of artemisinin-based 
combination therapies since 2014, but most available 
therapies include artemisinin derivatives from 
agricultural sources. Compounds readily produced by 
simple and inexpensive synthetic methods are clearly 
preferred.
Finally, some antimalarial drugs have safety 
limitations. Ideal antimalarial drugs must be safe in 
young children and pregnant women to enable treat-
ment and also use of these drugs for malaria control 
and elimination, including intermittent preventive 
therapy, seasonal malaria chemoprevention, and mass 
drug administration.
Key advantages of artefenomel are its lack of 
reliance on natural product starting materials, ease 
of synthesis,8 excellent absorption, distribution, 
metabolism, and excretion (ADME) properties,9 and, 
in limited studies, apparent safety10 and antimalarial 
eﬃ  cacy.2 In their phase 2a dose-ranging study, Phyo 
and colleagues show that the drug has excellent 
eﬃ  cacy against falciparum and vivax malaria on the 
basis of parasite clearance rates; true eﬃ  cacy was not 
assessed, because patients received deﬁ nitive therapy 
after 36 h. Safety results were reassuring, although a 
study of 80 patients is obviously limited in uncovering 
uncommon toxic efects. Importantly, artefenomel has 
a long half-life (46–62 h compared with about 0·5–4 h 
for artemisinins), and drug exposure did not seem to 
be decreased in acute malaria (as was the case with 
the earlier trioxolane arterolane [OZ277]11), leading to 
conﬁ dence that single-dose therapy will be feasible.10
But, artefenomel is not the perfect antimalarial 
drug. Its similarity to artemisinins suggests that 
it might share safety concerns; these drugs have 
proven to be very safe in routine use, including in 
young children, but they may be embryotoxic,12 
complicating use during pregnancy, and delayed 
haemolysis after therapy has been reported.13 As with 
artemisinins, artefenomel does not seem to have 
activity against liver stages, but it might oﬀ er at least 
partial transmission-blocking activity against sexual 
stages.14 Additionally, it remains unclear whether 
artefenomel will be subject to the same resistance 
concerns as artemisinins. In the current study, patients 
infected with artemisinin-resistant parasites (based 
on genotypes) cleared parasitaemia slightly (but not 
signiﬁ cantly) more slowly than did those infected 
with sensitive parasites,2 a result that is better than 
would be expected for artemisinins. However, with 
limited available data it remains uncertain whether 
artefenomel will circumvent artemisinin resistance.
In summary, artefenomel will probably be a long-acting 
artemisinin-related drug, oﬀ ering single-dose therapy, 
which is a major advance. Possibly, it will be equally active 
against wild-type and artemisinin-resistant parasites, a 
second major advance. Combination therapy is needed, 
and potential combinations are under investigation. 
The list of potential partner drugs remains short, and 
so continued work towards identifying additional new 
antimalarial drugs meeting the criteria discussed above is 
a high priority.
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We do not know how to prevent catheter-associated 
urinary tract infection (CAUTI). If a urinary catheter is 
placed in a patient and left in place for several weeks, 
they develop bacteriuria.1 Thus, CAUTIs have remained 
obstinate despite various eﬀ orts to induce hospitals to 
reduce them—eg, increased transparency of reporting 
infections (mandatory public reporting), penalisation 
of hospitals (value-based purchasing and hospital-
acquired condition reduction programmes), use of 
antiseptic coated urinary catheters, and promulgation 
and application of various prevention guidelines.2 So 
far, the best way to prevent CAUTI is to restrict the 
use of urinary catheters, and further progress in the 
parsimonious use of catheters can undoubtedly be 
achieved. However, if the care of a patient requires use 
of a urinary catheter, we do not know how to prevent 
nearly all catheterised patients from developing 
bacteriuria and some proportion eventually 
developing symptomatic UTI. Thus, innovative means 
to prevent CAUTI are needed.  
In this issue of The Lancet Infectious Diseases, 
Susan Huang and colleagues examine the use of whole-
body decolonisation with chlorhexidine bathing in 
preventing bacteriuria.3 In a secondary analysis of 
data from a pragmatic, large, cluster-randomised trial 
mainly designed to establish whether decolonisation 
using chlorhexidine bathing and nasal mupirocin 
prevented meticillin-resistant Staphylococcus aureus 
(MRSA) infection in patients in an intensive care 
unit (ICU),4 the authors noted that all bacteriuria and 
high-level candiduria were decreased in men. Nearly 
123 000 patients in 74 adult ICUs of 43 hospitals were 
assigned to either MRSA screening and isolation, 
targeted decolonisation, or universal decolonisation. 
Proportion hazard models were used to assess diﬀ erences 
between groups. No diﬀ erences were recorded for high-
level bacteriuria. Signiﬁ cant diﬀ erences in high-level 
candiduria were reported between groups and among 
men, but not among women. In the assessment of low-
level bacteriuria, no overall diﬀ erences were noted, but 
signiﬁ cant diﬀ erences in men were noted in comparison 
of universal decolonisation with screening and isolation. 
These interesting ﬁ ndings are presumably due to 
the reduction of microbial ﬂ ora in the perineum and 
periurethral tissues that was the result of chlorhexidine 
bathing. The little beneﬁ t in women could be because of 
anatomical diﬀ erences, making the urethral meatus less 
amendable to microbial decolonisation than in men.  
These data are interesting, but the study has 
several limitations and many questions still remain. 
Do chlorhexidine patient baths prevent catheter-associated 
urinary tract infections?
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